Acrivon Therapeutics, Inc. Common Stock (ACRV)
ACRV Stock Price Chart
Explore Acrivon Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze ACRV price movements and trends.
ACRV Company Profile
Discover essential business fundamentals and corporate details for Acrivon Therapeutics, Inc. Common Stock (ACRV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Nov 2022
Employees
75.00
Website
https://www.acrivon.comCEO
Peter Blume-Jensen
Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Financial Timeline
Browse a chronological timeline of Acrivon Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.57.
Earnings released on 13 Aug 2025
EPS came in at -$0.55 surpassing the estimated -$0.57 by +3.51%.
Earnings released on 14 May 2025
EPS came in at -$0.51 surpassing the estimated -$0.57 by +10.53%.
Earnings released on 27 Mar 2025
EPS came in at -$0.60 surpassing the estimated -$0.69 by +13.04%.
Earnings released on 13 Nov 2024
EPS came in at -$0.59 falling short of the estimated -$0.56 by -5.36%.
Earnings released on 13 Aug 2024
EPS came in at -$0.52 surpassing the estimated -$0.59 by +11.86%.
Earnings released on 14 May 2024
EPS came in at -$0.73 surpassing the estimated -$0.89 by +17.98%.
Earnings released on 28 Mar 2024
EPS came in at -$0.86 falling short of the estimated -$0.72 by -19.44%, while revenue for the quarter reached $1.88M .
Earnings released on 9 Nov 2023
EPS came in at -$0.66 surpassing the estimated -$0.72 by +8.33%.
Earnings released on 11 Aug 2023
EPS came in at -$0.63 surpassing the estimated -$0.68 by +7.35%.
Earnings released on 9 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.60 by +3.33%.
Earnings released on 28 Mar 2023
EPS came in at -$0.80 surpassing the estimated -$1.09 by +26.61%.
Earnings released on 14 Nov 2022
EPS came in at -$0.47 surpassing the estimated -$2.44 by +80.78%.
Earnings released on 14 Aug 2022
EPS came in at -$0.44 .
Earnings released on 15 May 2022
EPS came in at -$0.56 .
Earnings released on 14 Feb 2022
EPS came in at -$0.17 .
Earnings released on 31 Dec 2021
EPS came in at -$0.34 .
ACRV Stock Performance
Access detailed ACRV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.